phlboss withdrawal

phlboss withdrawal Cipher Pharmaceuticals Partner Moberg Pharma AB Reports Topline Data in MOB-015 Phase 3 StudyTORONTO, Dec. 13, 2024 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. EDSA , a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported financial results for the fiscal year ended September 30, 2024 and provided an update on its business. During the fiscal year, the company pivoted the in-house development of its anti-TLR4 drug candidate, EB05 (paridiprubart), to a U.S. government-funded study investigating novel threat-agnostic host-directed therapeutics in patients with Acute Respiratory Distress Syndrome (ARDS). Given this opportunity, Edesa is also amending a development and drug manufacturing project for the same asset that is supported by the Government of Canada. The company said that the goal is to maximize synergies between the two government-funded projects. For its anti-CXCL10 program, Edesa intends to manufacture EB06 and submit related data to the U.S. Food and Drug Administration as part of an investigational new drug (IND) application. The manufacturing of clinical-grade drug batches and initiation of the patient enrollment is subject to funding. Edesa anticipates topline results for this Phase 2 study could be available within as few as 12 to 18 months following regulatory clearance in the U.S. The study is currently approved in Canada. "This year, Edesa maintained its momentum despite the headwinds in the drug development sector, and we once again validated our TLR4 technology with a third competitive government award," said Par Nijhawan, MD, Chief Executive Officer of Edesa Biotech. "I have maintained my strategic support financially and I believe that our team can continue to advance and expand our development pipeline and partnerships." Edesa's Chief Financial Officer Stephen Lemieux reported that financial results for the fiscal year benefited from prudent use of working capital and effective financial management, including a more than 20% decrease in operating expenses. "Following the end of the fiscal year, we strengthened our balance sheet, and with two governments now funding the advancement of our anti-TLR4 technology, we have improved our position for future financing, potential strategic arrangements as well as other opportunities to advance our pipeline." Financial Results for the Fiscal Year Ended September 30, 2024 Total operating expenses decreased by $2.2 million to $7.0 million for the year ended September 30, 2024 compared to $9.2 million for the prior year: Research and development expenses decreased by $1.9 million to $2.9 million for the year ended September 30, 2024 compared to $4.8 million for the prior year primarily due to decreased external research expenses related to the company's completed dermatitis study and a reduction in labor costs and noncash share-based compensation, which were partially offset by an increase in expenses related to manufacturing of paridiprubart. General and administrative expenses decreased by $0.3 million to $4.1 million for year ended September 30, 2024 compared to $4.4 million for the prior year primarily due to a decrease in noncash share-based compensation, which was partially offset by an increase salaries and related costs. Total other income was unchanged at $0.8 million for the years ended September 30, 2024 and September 30, 2023 as a $0.1 million increase in reimbursement funding from the Canadian government's Strategic Innovation Fund was offset by a $0.1 million decrease in interest income. For the year ended September 30, 2024, Edesa reported a net loss of $6.2 million, or $1.93 per common share, compared to a net loss of $8.4 million, or $2.93 per common share, for the year ended September 30, 2023. Working Capital At September 30, 2024, Edesa had cash and cash equivalents of $1.0 million and negative working capital of $0.2 million. Subsequent to the fiscal year end, the company received $1.5 million in gross proceeds under a securities purchase agreement with an entity affiliated with Edesa's Chief Executive Officer and Founder, and $0.6 million in net proceeds, after deducting sales agent commissions, from common shares sold under an at-the-market offering program. Calendar Edesa management plans to participate in one-on-one meetings during JP Morgan week, which begins on January 13, 2025, in San Francisco, California. Attendees interested in meeting with management can request meetings through the conference organizers or by contacting Edesa directly at investors@edesabiotech.com . About Edesa Biotech, Inc. Edesa Biotech, Inc. EDSA is a clinical-stage biopharmaceutical company developing innovative ways to treat inflammatory and immune-related diseases. Its clinical pipeline is focused on two therapeutic areas: Medical Dermatology and Respiratory. In Medical Dermatology, Edesa is developing EB06, an anti-CXCL10 monoclonal antibody candidate, as therapy for vitiligo, a common autoimmune disorder that causes skin to lose its color in patches. Its medical dermatology assets also include EB01 (1.0% daniluromer cream), a Phase 3-ready asset developed for use as a potential therapy for moderate-to-severe chronic Allergic Contact Dermatitis (ACD), a common occupational skin condition. The company's most advanced Respiratory drug candidate is EB05 (paridiprubart), which is being evaluated in a U.S. government-funded platform study as a treatment for Acute Respiratory Distress Syndrome (ARDS), a life-threatening form of respiratory failure. The EB05 program has been the recipient of two funding awards from the Government of Canada to support the further development of this asset. In addition to EB05, Edesa is preparing an investigational new drug application (IND) in the United States for EB07 (paridiprubart) to conduct a future Phase 2 study in patients with pulmonary fibrosis. Sign up for news alerts . Connect with us on X and LinkedIn . Edesa Forward-Looking Statements This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may be identified by the use of words such as "anticipate," "believe," "plan," "estimate," "expect," "intend," "may," "will," "would," "could," "should," "might," "potential," or "continue" and variations or similar expressions, including statements related to: Edesa's ability to pivot the in-house development of its anti-TLR4 drug candidate; the company's plans to amend its contribution agreement with the Government of Canada; the company's goal to maximize synergies between two government-funded projects; Edesa plans to manufacture EB06 and submit related data to the FDA as part of an IND application; the company's plans to manufacture clinical-grade drug and initiate patient enrollment; the company's plans to finance clinical and manufacturing activities; the company's estimate that topline results for its Phase 2 vitiligo study could be available within as few as 12 to 18 months following regulatory clearance; the company's belief that in 2024 it maintained its momentum despite the headwinds in the drug development sector and once again validated its TLR4 technology with a third competitive government award; the company's belief that its team can continue to advance and expand its development pipeline and partnerships; the company's belief that its fiscal year financial results benefited from prudent use of working capital and effective financial management; the company's belief that with two governments funding the advancement of its anti-TLR4 technology, it has improved its position for future financing, potential strategic arrangements and alternatives as well as other opportunities to advance its pipeline; and the company's timing and plans regarding its clinical studies in general. Readers should not unduly rely on these forward-looking statements, which are not a guarantee of future performance. There can be no assurance that forward-looking statements will prove to be accurate, as all such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results or future events to differ materially from the forward-looking statements. Such risks include: the ability of Edesa to obtain regulatory approval for or successfully commercialize any of its product candidates, the risk that access to sufficient capital to fund Edesa's operations may not be available or may be available on terms that are not commercially favorable to Edesa, the risk that Edesa's product candidates may not be effective against the diseases tested in its clinical trials, the risk that Edesa fails to comply with the terms of license agreements with third parties and as a result loses the right to use key intellectual property in its business, Edesa's ability to protect its intellectual property, the timing and success of submission, acceptance and approval of regulatory filings, and the impacts of public health crises. Many of these factors that will determine actual results are beyond the company's ability to control or predict. For a discussion of further risks and uncertainties related to Edesa's business, please refer to Edesa's public company reports filed with the U.S. Securities and Exchange Commission and the British Columbia Securities Commission. All forward-looking statements are made as of the date hereof and are subject to change. Except as required by law, Edesa assumes no obligation to update such statements. Consolidated Statements of Operations Years Ended September 30, 2024 September 30, 2023 Expenses: Research and development $ 2,881,967 $ 4,794,549 General and administrative 4,132,777 4,428,209 Loss from operations (7,014,744 ) (9,222,758 ) Other Income (Loss): Reimbursement grant income 698,277 581,039 Other income (loss) 147,222 268,104 Income tax expense 800 800 Net loss (6,170,045 ) (8,374,415 ) Exchange differences on translation (27,965 ) (1,046 ) Net comprehensive loss $ (6,198,010 ) $ (8,375,461 ) Weighted average number of common shares 3,197,423 2,858,929 Loss per common share - basic and diluted $ (1.93 ) $ (2.93 ) Consolidated Balance Sheets September 30, 2024 September 30, 2023 Assets: Cash and cash equivalents $ 1,037,320 $ 5,361,397 Other current assets 638,302 1,075,455 Non-current assets 2,138,360 2,453,585 Total Assets $ 3,813,982 $ 8,890,437 Liabilities and shareholders' equity: Current liabilities $ 1,832,827 $ 1,821,864 Non-current liabilities - 19,773 Shareholders' equity 1,981,155 7,048,800 Total liabilities and shareholders' equity $ 3,813,982 $ 8,890,437 Consolidated Statements of Cash Flows Years Ended September 30, 2024 September 30, 2023 Cash flows from operating activities: Net loss $ (6,170,045 ) $ (8,374,415 ) Adjustments for non-cash items 708,775 1,429,928 Change in working capital items 571,065 308,004 Net cash used in operating activities (4,890,205 ) (6,636,483 ) Net cash provided by financing activities 592,031 4,830,111 Effect of exchange rate changes on cash and cash equivalents (25,903 ) 76,850 Net change in cash and cash equivalents (4,324,077 ) (1,729,522 ) Cash and cash equivalents, beginning of year 5,361,397 7,090,919 Cash and cash equivalents, end of year $ 1,037,320 $ 5,361,397 © 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.CHARLESTON, S.C. (AP) — Bryce Thompson scored 17 points, Marchelus Avery had 15 points and eight rebounds, and Oklahoma State beat Miami 80-74 on Friday in the consolation bracket of the Charleston Classic. Oklahoma State (4-1) will play in the fifth-place game on Sunday, while Miami (3-2) will try to avoid going winless in the tournament. Javascript is required for you to be able to read premium content. Please enable it in your browser settings.

Bucks get second crack at NBA Cup semis vs. Trae Young, HawksEgypt Urges Syrian-Led Political Process Following Assad's OverthrowThe 20 missing absentee ballots voters cast in the closely watched Minnesota House race between DFL Rep. Brad Tabke and Republican Aaron Paul were likely thrown away before being tabulated, according to Scott County Attorney Ron Hocevar. He blamed the episode on “human error” in a Wednesday update about an ongoing investigation into the situation. Hocevar’s message came a day after House Republicans announced they would file an election contest lawsuit in the Shakopee-area District 54A race, saying in a Tuesday statement that the missing ballots have “obscured the results of the final vote tally.” On Wednesday, the party issued a news release saying the House Republican Campaign Committee is expected to formally file that contest as early as Friday. “Today’s news confirms why we will be seeking an election contest to protect the integrity of the vote in District 54A with a new election,” House Minority Leader Lisa Demuth, R-Cold Spring, said in the news release. “With 20 ballots missing and confirmation from Scott County that they will likely not be recovered, it’s impossible to declare a winner with a 14 vote margin.” Tabke, who has a 14-vote lead over Paul, is on track to retain his seat after the Scott County Canvassing Board met Monday to certify the results of a recount . If Tabke and Dan Wolgamott, another DFL representative in a St. Cloud-area district, officially win their protracted contests , DFLers and Republicans will share power in the House for the first time since 1979. Scott County’s investigation centers on 20 absentee ballots checked in at Shakopee’s 10th Precinct for which officials can’t account. (Also missing is an absentee ballot in Precinct 12A, though staff opted not to pursue that discrepancy after noting it’s not uncommon for one voter to check in and not vote.) Tracking envelopes A three-page preliminary investigation summary released Wednesday outlines how the county determined those 10th precinct absentee ballots were most likely discarded. One key to the initial findings? Envelopes. Multiple sleeves encase absentee ballots in Minnesota . An inner envelope, known as a secrecy sleeve, contains the ballot but no identifying information about the voter to protect their privacy. That goes inside another envelope, known as a signature sleeve, that the voter signs. And that all gets placed inside the envelope use for mailing. In the 54A race, an absentee ballot board followed the standard procedure for accepting or rejecting absentee ballots, the summary states. Members first examined the signature sleeves and recorded them into a statewide registration system. They then divided those envelopes by precinct before opening the signature and secrecy sleeves, removing the ballots and preparing them for tabulation. As part of the investigation, county staff asked the city for the secrecy envelopes tied to the 20 missing ballots. That’s when staff learned those liners had been thrown out, prompting the county to track trash and recycling. The trash sat at a Burnsville landfill, according to the summary. The recycling, located at a Dem-Con facility, had already been sent for shredding. That led to the conclusion outlined in the preliminary summary: the ballots were likely thrown out while they remained in the secrecy envelopes before being tabulated. “This unfortunate situation resulted in a level of confusion that should not have occurred,” Hocevar said in a statement, adding that the investigation remains ongoing. He said in the summary that the ballots will most likely not be recovered, adding that even if they’re found, “it is unlikely that their chain of custody can be proven to assure they have not been tampered with.” Demuth, the Republican representative, previously called on called on Scott County to “prove chain of custody if the ballots are located and guarantee that there was not malicious activity” that led to the ballots “being removed or destroyed.” Tight race for House seat The update is the latest development in the protracted fight for the District 54A seat — tight since election day. Early returns showed Paul, a Bloomington police officer, ahead in several precincts by small margins. Tabke, a former Shakopee mayor who has served two nonconsecutive House terms, maintained advantages in northeast Shakopee and a precinct north of Shakopee High School. A few days after election night, Scott County officials rescanned some ballots cast in Shakopee after a scanning machine malfunction. The updated unofficial results increased Tabke’s advantage by one vote, to 14. Paul then requested a recount, with the margin between the two contenders remaining within the threshold set by state law for a taxpayer-funded one. Tabke led Paul by 14 votes after the Scott County Canvassing Board convened Nov. 25 to certify the recount’s results. A day later, House Republicans announced their intent to contest the race.

Alberta pulls plug (again) on regional planning

Ruto defends record on economy, accuses State critics of telling lies

In response to statements on recent verdicts by military courts, the Foreign Office on Tuesday reaffirming Pakistan's commitment to fulfilling all its international human rights obligations, said that the verdicts had been made under a law enacted by the Parliament of Pakistan and in line with the judgment of the Supreme Court of Pakistan ISLAMABAD, (UrduPoint / Pakistan Point News - 24th Dec, 2024) In response to statements on recent verdicts by military courts, the on Tuesday reaffirming 's commitment to fulfilling its international human rights obligations, said that the verdicts had been made under a law enacted by the of and in line with the judgment of the of . "Pakistan’s legal system is consistent with international human rights law including provisions of the International Covenant on Civil and Political Rights (ICCPR)," the FO spokesperson said in a statement. The spokesperson added that the country's legal system had remedies of judicial review by the courts and guaranteed promotion and protection of human rights and fundamental freedoms. The statement added that believed in constructive and productive dialogue to promote principles of , human rights and the rule of law. "We remain fully committed to implementing our commitments under the GSP Plus Scheme and core international human rights conventions," the spokesperson said adding "We will continue to engage with our international partners including the to uphold the international human rights law, without any discrimination and double standards".None

TORONTO, Dec. 13, 2024 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported financial results for the fiscal year ended September 30, 2024 and provided an update on its business. During the fiscal year, the company pivoted the in-house development of its anti-TLR4 drug candidate, EB05 (paridiprubart), to a U.S. government-funded study investigating novel threat-agnostic host-directed therapeutics in patients with Acute Respiratory Distress Syndrome (ARDS). Given this opportunity, Edesa is also amending a development and drug manufacturing project for the same asset that is supported by the Government of Canada. The company said that the goal is to maximize synergies between the two government-funded projects. For its anti-CXCL10 program, Edesa intends to manufacture EB06 and submit related data to the U.S. Food and Drug Administration as part of an investigational new drug (IND) application. The manufacturing of clinical-grade drug batches and initiation of the patient enrollment is subject to funding. Edesa anticipates topline results for this Phase 2 study could be available within as few as 12 to 18 months following regulatory clearance in the U.S. The study is currently approved in Canada. “This year, Edesa maintained its momentum despite the headwinds in the drug development sector, and we once again validated our TLR4 technology with a third competitive government award,” said Par Nijhawan, MD, Chief Executive Officer of Edesa Biotech. “I have maintained my strategic support financially and I believe that our team can continue to advance and expand our development pipeline and partnerships.” Edesa's Chief Financial Officer Stephen Lemieux reported that financial results for the fiscal year benefited from prudent use of working capital and effective financial management, including a more than 20% decrease in operating expenses. “Following the end of the fiscal year, we strengthened our balance sheet, and with two governments now funding the advancement of our anti-TLR4 technology, we have improved our position for future financing, potential strategic arrangements as well as other opportunities to advance our pipeline.” Financial Results for the Fiscal Year Ended September 30, 2024 Total operating expenses decreased by $2.2 million to $7.0 million for the year ended September 30, 2024 compared to $9.2 million for the prior year: Research and development expenses decreased by $1.9 million to $2.9 million for the year ended September 30, 2024 compared to $4.8 million for the prior year primarily due to decreased external research expenses related to the company’s completed dermatitis study and a reduction in labor costs and noncash share-based compensation, which were partially offset by an increase in expenses related to manufacturing of paridiprubart. General and administrative expenses decreased by $0.3 million to $4.1 million for year ended September 30, 2024 compared to $4.4 million for the prior year primarily due to a decrease in noncash share-based compensation, which was partially offset by an increase salaries and related costs. Total other income was unchanged at $0.8 million for the years ended September 30, 2024 and September 30, 2023 as a $0.1 million increase in reimbursement funding from the Canadian government's Strategic Innovation Fund was offset by a $0.1 million decrease in interest income. For the year ended September 30, 2024, Edesa reported a net loss of $6.2 million, or $1.93 per common share, compared to a net loss of $8.4 million, or $2.93 per common share, for the year ended September 30, 2023. Working Capital At September 30, 2024, Edesa had cash and cash equivalents of $1.0 million and negative working capital of $0.2 million. Subsequent to the fiscal year end, the company received $1.5 million in gross proceeds under a securities purchase agreement with an entity affiliated with Edesa’s Chief Executive Officer and Founder, and $0.6 million in net proceeds, after deducting sales agent commissions, from common shares sold under an at-the-market offering program. Calendar Edesa management plans to participate in one-on-one meetings during JP Morgan week, which begins on January 13, 2025, in San Francisco, California. Attendees interested in meeting with management can request meetings through the conference organizers or by contacting Edesa directly at investors@edesabiotech.com . About Edesa Biotech, Inc. Edesa Biotech, Inc. (Nasdaq: EDSA) is a clinical-stage biopharmaceutical company developing innovative ways to treat inflammatory and immune-related diseases. Its clinical pipeline is focused on two therapeutic areas: Medical Dermatology and Respiratory. In Medical Dermatology, Edesa is developing EB06, an anti-CXCL10 monoclonal antibody candidate, as therapy for vitiligo, a common autoimmune disorder that causes skin to lose its color in patches. Its medical dermatology assets also include EB01 (1.0% daniluromer cream), a Phase 3-ready asset developed for use as a potential therapy for moderate-to-severe chronic Allergic Contact Dermatitis (ACD), a common occupational skin condition. The company’s most advanced Respiratory drug candidate is EB05 (paridiprubart), which is being evaluated in a U.S. government-funded platform study as a treatment for Acute Respiratory Distress Syndrome (ARDS), a life-threatening form of respiratory failure. The EB05 program has been the recipient of two funding awards from the Government of Canada to support the further development of this asset. In addition to EB05, Edesa is preparing an investigational new drug application (IND) in the United States for EB07 (paridiprubart) to conduct a future Phase 2 study in patients with pulmonary fibrosis. Sign up for news alerts . Connect with us on X and LinkedIn . Edesa Forward-Looking Statements This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may be identified by the use of words such as "anticipate," "believe," "plan," "estimate," "expect," "intend," "may," "will," "would," "could," "should," "might," "potential," or "continue" and variations or similar expressions, including statements related to: Edesa’s ability to pivot the in-house development of its anti-TLR4 drug candidate; the company’s plans to amend its contribution agreement with the Government of Canada; the company’s goal to maximize synergies between two government-funded projects; Edesa plans to manufacture EB06 and submit related data to the FDA as part of an IND application; the company’s plans to manufacture clinical-grade drug and initiate patient enrollment; the company’s plans to finance clinical and manufacturing activities; the company’s estimate that topline results for its Phase 2 vitiligo study could be available within as few as 12 to 18 months following regulatory clearance; the company’s belief that in 2024 it maintained its momentum despite the headwinds in the drug development sector and once again validated its TLR4 technology with a third competitive government award; the company’s belief that its team can continue to advance and expand its development pipeline and partnerships; the company’s belief that its fiscal year financial results benefited from prudent use of working capital and effective financial management; the company’s belief that with two governments funding the advancement of its anti-TLR4 technology, it has improved its position for future financing, potential strategic arrangements and alternatives as well as other opportunities to advance its pipeline; and the company's timing and plans regarding its clinical studies in general. Readers should not unduly rely on these forward-looking statements, which are not a guarantee of future performance. There can be no assurance that forward-looking statements will prove to be accurate, as all such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results or future events to differ materially from the forward-looking statements. Such risks include: the ability of Edesa to obtain regulatory approval for or successfully commercialize any of its product candidates, the risk that access to sufficient capital to fund Edesa's operations may not be available or may be available on terms that are not commercially favorable to Edesa, the risk that Edesa's product candidates may not be effective against the diseases tested in its clinical trials, the risk that Edesa fails to comply with the terms of license agreements with third parties and as a result loses the right to use key intellectual property in its business, Edesa's ability to protect its intellectual property, the timing and success of submission, acceptance and approval of regulatory filings, and the impacts of public health crises. Many of these factors that will determine actual results are beyond the company's ability to control or predict. For a discussion of further risks and uncertainties related to Edesa's business, please refer to Edesa's public company reports filed with the U.S. Securities and Exchange Commission and the British Columbia Securities Commission. All forward-looking statements are made as of the date hereof and are subject to change. Except as required by law, Edesa assumes no obligation to update such statements.

Top asset managers falling short of labour expectationsAll you have to do to become a South Dakota resident is spend one night. Stay in a campground or hotel and then stop by one of the businesses that specialize in helping people become South Dakotans, and they’ll help you do the paperwork to gain residency in a state with no income tax and relatively cheap vehicle registration. The system brings in extra government revenue through vehicle fees and offers refuge to full-time travelers who wouldn’t otherwise have a permanent address or a place to vote. And that’s the problem. State leaders are at a stalemate between those who say people who don’t really live in South Dakota shouldn’t be allowed to vote in local elections and those who say efforts to impose a longer residency requirement for voting violate the principle that everyone gets to vote. And at least one state has gotten wind that its residents might be avoiding high income taxes with easy South Dakota residency and is investigating. Catering to the nomadic lifestyle for nomads has become an enterprising opportunity for businesses such as RV parks and mail forwarders. “That’s the primary concept here, is the people that have given up their sticks and bricks and now are on wheel estate, we call it, and they’re full-time traveling,” said Dane Goetz, owner of the Spearfish-based South Dakota Residency Center, which caters to full-time travelers. “They need a place to call home, and we provide that address for them to do that, and they are just perpetually on the move.” Goetz estimated more than 30,000 people are full-time traveler residents of South Dakota, but the actual number is unclear. The state Department of Public Safety, which handles driver licensing, says it doesn’t track the number of full-time traveler applications. Officials of the South Dakota Secretary of State’s Office did not respond to emailed questions or a phone message seeking the state’s tally of full-time travelers registered to vote. The office is not responsible for enforcing residency requirements, Division of Elections Director Rachel Soulek said. Victor Robledo, his wife and their five kids hit the road a decade ago in a 28-foot (8.5-meter) motorhome to seek adventure and ease their high cost of living in Southern California. They found South Dakota to be an opportunity to save money, receive mail and “take a residency in a state that really nurtures us,” he said. They filed for residency in 2020. “It was as simple as coming into the state, staying one night in one of the campgrounds, and once we do that, we bring in a receipt to the office, fill out some paperwork, change our licenses. I mean, really, you can blow through there — gosh, 48 hours,” Robledo said. Residency rules spark election concerns Residency becomes thorny around voting. Some opponents don’t want people who don’t physically live in South Dakota to vote in its elections. “I don’t want to deny somebody their right to vote, but to think that they can vote in a school board election or a legislative election or a county election when they’re not part of the community, I’m troubled by that,” said Democratic Rep. Linda Duba, who cited 10,000 people or roughly 40% of her Sioux Falls constituents being essentially mailbox residents. She likes to knock on doors and meet people but said she is unable to do “relationship politics” with travelers. The law the Republican-controlled Legislature passed in 2023 added requirements for voter registration, including 30 days of residency — which don’t have to be consecutive — and having “an actual fixed permanent dwelling, establishment, or any other abode to which the person returns after a period of absence.” The bill’s prime sponsor, Republican Sen. Randy Deibert, told a Senate panel that citizens expressed concerns about “people coming to the state, being a resident overnight and voting (by) absentee ballot or another way the next day and then leaving the state.” Those registered to vote before the new law took effect remain registered, but some who tried to register since its passage had trouble. Dozens of people recently denied voter registration contacted the American Civil Liberties Union of South Dakota, according to the chapter’s advocacy manager, Samantha Chapman. Durational residency requirements for voting are, in general, unconstitutional because such restrictions interfere with the interstate right to travel, said David Schultz, a Hamline University professor of political science and a professor of law at the University of St. Thomas. “It’s kind of this parochialism, this idea of saying that only people who are really in our neighborhood, who really live in our city have a sufficient stake in it, and the courts have generally been unsympathetic to those types of arguments because, more often than not, they’re used for discriminatory purposes,” he said. State lawmakers at odds over residency law Earlier this year, the Legislature considered a bill to roll back the 2023 law. It passed the Senate but stalled in the House. During a House hearing on that bill, Republican Rep. Jon Hansen asked one full-time traveler when he was last in South Dakota and when he intends to return. The man said he was in the state a year earlier but planned to return in coming months. Another man who moved from Iowa to work overseas said he had not lived “for any period of time, physically” in South Dakota. “I don’t think we should allow people who have never lived in this state to vote in our state,” Hansen said. Republican Sen. David Wheeler, an attorney in Huron, said he expects litigation would be what forces a change. It’s unlikely a change to the 30-day requirement would pass the Legislature now, he said. “It is a complicated topic that involves federal and state law and federal and state voting rights, and it is difficult to bring everybody together on how to appropriately address that,” Wheeler said. Out-of-state residents may see tax benefits More than 1,600 miles (2,500 kilometers) east, Connecticut State Comptroller Sean Scanlon has asked prosecutors to look into whether some state employees who live in Connecticut may have skirted their tax obligations by claiming to be residents of South Dakota. Connecticut has a graduated income tax rate of 3.0% to 6.99%. Connecticut cities and towns also impose a property tax on vehicles. South Dakota has none. Scanlon and his office, which administers state employee retiree benefits, learned from a Hartford Courant columnist in September that some state retirees might be using South Dakota’s mail-forwarding services for nefarious reasons. Asked if there are concerns about other Connecticut taxpayers who are not state retirees possibly misusing South Dakota’s lenient residency laws, the Department of Revenue Services would only say the agency is “aware of the situation and we’re working with our partners to resolve it.” A South Dakota legislative panel broached the residency issue as recently as August, a meeting in which one lawmaker called the topic “the Gordian knot of politics.” “It seems like it’s almost impossible to come to some clear and definitive statement as to what constitutes a residency with such a mobile population with people with multiple homes and addresses and political boundaries that are easy to see on a map but there’s so much cross-transportation across them,” Republican Sen. Jim Bolin said. ___ Dura reported from Bismarck, North Dakota. Associated Press Writer Susan Haigh in Hartford, Connecticut, contributed to this report. Jack Dura, The Associated PressZionist PM testifies in corruption trial